KSENIA NAWROCKI: Open Payments
NPI 1487882742 · CHULA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,903 in 72 payments from 9 companies in 2025. Trend: 2023 $918 · 2024 $1,325 · 2025 $1,903
Food & beverage: $1,834Education: $70
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 17 | $435 |
| E.R. Squibb & Sons, L.L.C. | 15 | $424 |
| Teva Pharmaceuticals USA, Inc. | 9 | $275 |
| Vanda Pharmaceuticals Inc. | 6 | $189 |
| ABBVIE INC. | 7 | $157 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $151 |
| Janssen Pharmaceuticals, Inc | 5 | $106 |
| Neurocrine BioSciences, Inc. | 4 | $87 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
Products named: COBENFY, ARISTADA, UZEDY, FANAPT, VRAYLAR, CAPLYTA, LYBALVI, INVEGA SUSTENNA.
Industry payments across CA — which companies pay providers there.
